Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells $522,543.96 in Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Shao-Lee Lin sold 18,258 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $28.62, for a total transaction of $522,543.96. Following the completion of the sale, the chief executive officer directly owned 705,995 shares of the company’s stock, valued at $20,205,576.90. The trade was a 2.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Wednesday, August 12th, Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock. The stock was sold at an average price of $27.10, for a total value of $1,084,000.00.

Cue Biopharma Price Performance

Shares of CUE stock opened at $34.20 on Monday. The stock’s 50-day moving average price is $29.50 and its 200 day moving average price is $146.00. The stock has a market capitalization of $143.64 million, a PE ratio of -1.27 and a beta of 2.47. Cue Biopharma, Inc. has a 52-week low of $4.97 and a 52-week high of $45.50.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings data on Friday, August 14th. The company reported ($24.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). Cue Biopharma had a negative return on equity of 482.58% and a negative net margin of 435.83%.The company had revenue of $7.88 million for the quarter, compared to analyst estimates of $3.00 million.

Institutional Investors Weigh In On Cue Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. GC Wealth Management RIA LLC boosted its position in shares of Cue Biopharma by 35.0% during the 4th quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company’s stock worth $1,415,000 after purchasing an additional 1,200,000 shares in the last quarter. Boothbay Fund Management LLC grew its stake in shares of Cue Biopharma by 15.3% during the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after purchasing an additional 93,333 shares during the period. Texas Capital Bank Wealth Management Services Inc increased its holdings in shares of Cue Biopharma by 1,231.2% in the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after purchasing an additional 407,568 shares in the last quarter. Stifel Financial Corp increased its holdings in shares of Cue Biopharma by 25.4% in the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Cue Biopharma in the third quarter valued at about $62,000. Institutional investors and hedge funds own 35.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on CUE shares. Weiss Ratings upgraded shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Wall Street Zen cut shares of Cue Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cue Biopharma has a consensus rating of “Sell”.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.